Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

ABSTRACT: Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

PROVIDER: PRJNA813527 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.

Project description:In contrast to the curative effect of allogenic stem cell transplantation in acute myeloid leukemia via T cell activity, only modest responses are achieved with checkpoint-blockade therapy, which might be explained by T cell phenotypes and T cell receptor (TCR) repertoires. Here, we show by paired single-cell RNA analysis and TCR repertoire profiling of bone marrow cells in relapsed/refractory acute myeloid leukemia patients pre/post azacytidine+nivolumab treatment that the disease-related T cell subsets are highly heterogeneous, and their abundance changes following PD-1 blockade-based treatment. TCR repertoires expand and primarily emerge from CD8+ cells in patients responding to treatment or having a stable disease, while TCR repertoires contract in therapy-resistant patients. Trajectory analysis reveals a continuum of CD8+ T cell phenotypes, characterized by differential expression of granzyme B and a bone marrow-residing memory CD8+ T cell subset, in which a population with stem-like properties expressing granzyme K is enriched in responders. Chromosome 7/7q loss, on the other hand, is a cancer-intrinsic genomic marker of PD-1 blockade resistance in AML. In summary, our study reveals that adaptive T cell plasticity and genomic alterations determine responses to PD-1 blockade in acute myeloid leukemia.

| S-EPMC8524723 | biostudies-literature

Blood-Tumor overlapping TCR repertoire predicts the clinical responses of PD-1 blockade in patients with gastrointestinal cancer [TCR-Seq]

Project description:As the anti-PD-1 monoclonal antibody (mAb) becomes to be used in many types of cancers, the needs for the predictive biomarker of PD-1 blockade are growing. T cell receptor (TCR) repertoire—which reflects the anti-tumor T-cell responses based on the antigen specificity—is a potential biomarker of cancer immunotherapy. Here, we analyzed the TCR repertoire of patients with advanced gastrointestinal cancer and explored its association with clinical responses.

2021-07-13 | GSE154536 | GEO

Blood-Tumor overlapping TCR repertoire predicts the clinical responses of PD-1 blockade in patients with gastrointestinal cancer[RNA-Seq]

2021-07-13 | GSE154538 | GEO

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Project description:We report the application of single cell RNA and TCR sequencing technology on 22 bone marrow aspirates from 8 AML patients. By exploring 60753 AML cells and 52641 tumor microenvironment cells, we show that TCR repertoires expand and primarily emerge from CD8+ cells in responsive patients, but contract in therapy-resistant patients.Tractory analysis reveals that CD8 + T cells in AML are on continuum with GZMK expression being enriched in a memory subset of CD8 + T cells. Also, Chromosome 7/7q loss s an intrinsic AML biomarker of resistance to ICB-therapy.

2022-03-10 | GSE198052 | GEO

T cell receptor repertoire profiling of murine skin transplantation in context of PD-1+ cells Ablation therapy

Project description:T cell receptor repertoire profiling of murine skin transplantation in context of PD-1+ cells Ablation therapy

| PRJNA896559 | ENA

T cell receptor repertoire in AML

Project description:Azacytidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients

| PRJEB48020 | ENA

Co-evolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case [TCR-seq]

Project description:JAK2V617+ myeloproliferative disease has been reported to overexpress PD-L1 rationalizing therapeutic PD-1 blockade. We performed an integrated single cell analysis on samples from an exceptional responder to nivolumab to elucidate determinants of response in this patient.

2021-08-26 | GSE165851 | GEO

Co-evolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case [BCR-seq]

2021-08-26 | GSE165850 | GEO

Co-evolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case [CITE-seq]

2021-08-26 | GSE165822 | GEO

Co-evolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case [RNA-seq]

2021-08-26 | GSE165496 | GEO